{"id":"rituximab-us","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Infusion reactions"},{"rate":"20-40","effect":"Infections"},{"rate":"10-30","effect":"Cytopenias (anemia, thrombocytopenia, neutropenia)"},{"rate":"10-20","effect":"Fatigue"},{"rate":"10-15","effect":"Fever"},{"rate":"5-10","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rituximab targets CD20, a surface antigen expressed on B lymphocytes. By binding to CD20, it triggers antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to B cell depletion. This mechanism reduces autoimmune responses and is effective in B-cell malignancies and autoimmune disorders.","oneSentence":"Rituximab is a monoclonal antibody that binds to CD20 on B cells, marking them for destruction by the immune system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:32:23.370Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-Hodgkin's lymphoma (B-cell)"},{"name":"Chronic lymphocytic leukemia (CLL)"},{"name":"Rheumatoid arthritis"},{"name":"Granulomatosis with polyangiitis (GPA)"},{"name":"Microscopic polyangiitis (MPA)"}]},"trialDetails":[{"nctId":"NCT04609046","phase":"PHASE1","title":"Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-24","conditions":"Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System","enrollment":47},{"nctId":"NCT04623541","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-11-25","conditions":"Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome","enrollment":195},{"nctId":"NCT04712097","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-27","conditions":"Relapsed or Refractory Follicular Lymphoma","enrollment":478},{"nctId":"NCT04268771","phase":"PHASE3","title":"A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2020-04-08","conditions":"Rheumatoid Arthritis","enrollment":140},{"nctId":"NCT04680962","phase":"PHASE3","title":"MabionCD20® Compared to MabThera® and Rituxan® in Patients With Rheumatoid Arthritis","status":"WITHDRAWN","sponsor":"Mabion SA","startDate":"2023-08-03","conditions":"Rheumatoid Arthritis","enrollment":""},{"nctId":"NCT02747043","phase":"PHASE3","title":"Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab","status":"COMPLETED","sponsor":"Amgen","startDate":"2016-05-25","conditions":"Lymphoma, Non-Hodgkin","enrollment":256},{"nctId":"NCT02149121","phase":"PHASE3","title":"PK Similarity Prospective Phase 3 Study in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Celltrion","startDate":"2014-08","conditions":"Rheumatoid Arthritis","enrollment":384},{"nctId":"NCT02792699","phase":"PHASE3","title":"Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to Rituximab","status":"COMPLETED","sponsor":"Amgen","startDate":"2016-05-17","conditions":"Arthritis, Rheumatoid","enrollment":311},{"nctId":"NCT01526057","phase":"PHASE2","title":"A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-03-20","conditions":"Rheumatoid Arthritis","enrollment":220},{"nctId":"NCT01643928","phase":"NA","title":"Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-08-16","conditions":"Rheumatoid Arthritis","enrollment":185},{"nctId":"NCT00774202","phase":"PHASE2, PHASE3","title":"Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2003-11","conditions":"Immune Thrombocytopenic Purpura","enrollment":17},{"nctId":"NCT01274182","phase":"PHASE1, PHASE2","title":"GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy","status":"COMPLETED","sponsor":"Sandoz","startDate":"2011-01","conditions":"Rheumatoid Arthritis","enrollment":312},{"nctId":"NCT02417129","phase":"PHASE3","title":"BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2015-04","conditions":"Lymphoma, Non-Hodgkin","enrollment":2},{"nctId":"NCT00656084","phase":"PHASE2","title":"Ph2 Gem/Nov/Rituxan Rel/Ref MantleCell","status":"COMPLETED","sponsor":"US Oncology Research","startDate":"2004-12","conditions":"Relapsed or Refractory Mantle Cell Lymphoma (MCL)","enrollment":16},{"nctId":"NCT01390441","phase":"PHASE1","title":"A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-07","conditions":"Rheumatoid Arthritis","enrollment":100},{"nctId":"NCT01765374","phase":"PHASE4","title":"Study of Sonographic Efficacy of Rituximab in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2011-02","conditions":"Rheumatoid Arthritis","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Rituxan®"],"phase":"phase_3","status":"active","brandName":"Rituximab (US)","genericName":"Rituximab (US)","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rituximab is a monoclonal antibody that binds to CD20 on B cells, marking them for destruction by the immune system. Used for Non-Hodgkin's lymphoma (B-cell), Chronic lymphocytic leukemia (CLL), Rheumatoid arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}